Prevalence of osteoporosis among patients after stem cell transplantation: a systematic review and meta-analysis

• Published in: Bone marrow transplantation (Basingstoke) Vol. 59; no. 6; pp. 785 - 794
• Main Authors: Yang, Yu-Mei, Guo, Shu-Jin, Xiao, Rong, Yu, Xi-Jie, Liu, Yu-Ping, Shuai, Ping
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.06.2024; Nature Publishing Group
• Subjects: 42/100; 631/532/1542; 692/699/67/1990/283; Blood diseases; Bone Density; Bone mineral density; Cell Biology; Female; Hematological diseases; Hematology; Heterogeneity; Humans; Internal Medicine; Male; Medical prognosis; Medicine; Medicine & Public Health; Meta-analysis; Osteopenia; Osteoporosis; Osteoporosis - diagnosis; Osteoporosis - epidemiology; Osteoporosis - etiology; Osteoporosis - prevention & control; Prevalence; Public Health; Stem cell transplantation; Stem Cell Transplantation - adverse effects; Stem Cells; Subgroups; Systematic review; Transplantation
• ISSN: 0268-3369; 1476-5365; 1476-5365
• DOI: 10.1038/s41409-024-02243-0

The prevalence of osteoporosis in post stem cell transplantation (SCT) is poorly defined. We performed a systematic review and meta-analysis to determine the prevalence of osteoporosis in patients with hematologic diseases who underwent SCT. PubMed, EMBASE, and Web of Science were searched (from inception to 30th April 2023) using Medical Subject Headlines to find studies that assessed the prevalence of osteoporosis among post SCT. Thirteen articles meeting the inclusion criteria were included in the analysis. The pooled prevalence rates of osteoporosis, osteopenia, and decreased bone mineral density (BMD) were determined to be 14.2% (95% CI 9.7–18.8), 36.0% (95% CI 23.8–48.2), and 47.8% (95% CI 36.6–58.9), respectively. Substantial heterogeneity was observed among the included studies (I² values ranged from 81% to 99%). Subgroup analyses revealed variations in prevalence based on gender, follow-up duration, age, region, sample size, and study quality. These findings suggest a high prevalence of osteoporosis in post-SCT patients. Given the negative impact of osteoporosis on prognosis and recipient survival, clinicians should prioritize preventive measures, early diagnosis, and effective treatments to minimize its impact.